Business Context and Reporting Period
This Form 8-K, dated May 4, 2018, reports the consummation of a business combination between Amneal Pharmaceuticals, Inc. (formerly Atlas Holdings, Inc.) and Impax Laboratories, Inc. (Impax). The transaction involved a merger where Impax became a wholly-owned subsidiary of Amneal, followed by a conversion of Impax to a limited liability company and a contribution of equity interests to Amneal Pharmaceuticals LLC. The Company changed its name from Atlas Holdings, Inc. to Amneal Pharmaceuticals, Inc. and began trading on the NYSE under the symbol "AMRX."
Key Financial Metrics and Capital Structure
Debt and Liquidity:
- Term Loan: Entered into a new Term Loan Credit Agreement with an initial aggregate principal amount of up to $2,700.0 million, maturing on May 4, 2025.
- Revolving Credit Facility (ABL): Entered into an Asset Based Lending (ABL) facility with an initial aggregate principal amount of up to $500.0 million, maturing on May 4, 2023. Up to $25 million is available for letters of credit.
- Debt Repayment: Net proceeds from the Term Loan were used to finance the transactions, pay fees, and pay off existing indebtedness. Approximately $1,920.3 million of existing debt under prior credit agreements was paid off in full.
- Interest Rates: Term Loan margins are initially 3.50% (LIBOR) or 2.50% (Base Rate). ABL margins are initially 1.50% (LIBOR) or 0.50% (Base Rate).
Equity and PIPE Investment:
- PIPE Transaction: Select institutional investors (including TPG and Fidelity) purchased shares for gross proceeds of approximately $855.0 million at a price of $18.25 per share.
- Ownership Structure: Following the transaction, Impax stockholders hold approximately 25% of voting power and 62.5% of economic interest. Existing Amneal members (via Amneal Holdings, LLC) hold approximately 60% of voting power with no economic interest. PIPE investors hold approximately 15% of voting power and 37.5% of economic interest.
Acquisition:
- Gemini Laboratories: Amneal acquired 98% of Gemini Laboratories, LLC for $40.0 million in cash, a $77.2 million promissory note, and assumed liabilities.
Revenue and Profit: This filing does not provide specific revenue, profit, or cash flow figures for the combined entity for the reporting period. Pro forma financial information is referenced as being filed in a separate Registration Statement on Form S-1.
Material Changes Versus Prior Period
- Corporate Identity: The registrant changed its name from Atlas Holdings, Inc. to Amneal Pharmaceuticals, Inc.
- Capital Structure: Significant restructuring of debt and equity occurred. Old credit facilities were terminated and replaced with new senior secured credit facilities totaling up to $3.2 billion in capacity.
- Accounting Firm: KPMG LLP was dismissed as the independent registered public accounting firm. Ernst & Young LLP (EY) was engaged to audit financial statements for the fiscal period beginning January 1, 2018.
- Management and Board: The board of directors was reconstituted. Chirag Patel and Chintu Patel were appointed Co-Chairmen. Several new directors were appointed, and previous directors/officers from Atlas Holdings resigned or changed roles.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook: The filing focuses on the structural completion of the merger and the establishment of new governance and financing frameworks. No specific forward-looking revenue or earnings guidance is provided in this document.
Risks and Covenants:
- Financial Covenants: The ABL Facility includes a financial maintenance covenant requiring a minimum fixed charge coverage ratio of 1.0:1.0, tested only if availability falls below specific thresholds.
- Restrictive Covenants: The new credit agreements contain negative covenants restricting additional debt, liens, acquisitions, asset dispositions, and dividends.
- Tax Receivable Agreement: The Company entered into a Tax Receivable Agreement to pay existing Amneal members 85% of the cumulative net realized tax benefits resulting from the step-up in tax basis of Amneal assets.
- Related Party Transactions: The acquisition of Gemini Laboratories is a related party transaction involving family members of the Company's Co-Chairmen.
Important Facts for Investor Verification
- Verify the pro forma financial statements and debt load impact in the referenced Form S-1 Registration Statement.
- Confirm the specific terms of the Tax Receivable Agreement and its potential impact on future cash flows.
- Review the integration plan and synergies expected from the combination of Amneal and Impax, as detailed in the proxy statement.
- Monitor the Company's ability to meet the fixed charge coverage ratio covenant under the new ABL facility.
- Assess the implications of the related party transaction regarding the acquisition of Gemini Laboratories.